Royal Hobart Hospital

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN126...

A feasibility study of combined hyperbaric oxygen treatment and a lifestyle medicine program for multimorbid conditions

Introduction: Multimorbidity and polypharmacy are highly prevalent among patients receiving hyperbaric oxygen treatment (HBOT). Lifestyle Medicine (LM) interventions improve health outcomes in chronic disease management, but their implementation in tertiary hospital settings rema...